Organon (OGN) Non-Current Assets (2020 - 2026)
Organon (OGN) posted Non-Current Assets of $8.1 billion for Q2 2026, little changed on a QoQ basis from $8.1 billion in Q1 2026, and down 9.18% year-over-year from $8.9 billion in Q2 2025.
Analysis
Organon (OGN) Non-Current Assets (2020 - 2026) Analysis & Trends
Organon has reported Non-Current Assets for 7 years, with the latest figure at $8.1 billion in Q2 2026.
- On a quarterly basis, Non-Current Assets fell 9.18% year-over-year to $8.1 billion in Q2 2026; TTM through Jun 2026 was $33.5 billion, a 2.67% decrease from a year earlier, with the FY2025 full-year figure at $8.5 billion, down 2.72% from the prior year.
- Non-Current Assets was $8.1 billion for Q2 2026 at Organon, roughly flat from $8.1 billion in the prior quarter.
- The five-year high for Non-Current Assets was $8.9 billion in Q2 2025, with the low at $6.8 billion in Q2 2022.
- Average Non-Current Assets over 5 years is $7.7 billion, with a median of $7.7 billion recorded in 2024.
- The sharpest annual moves came in 2025 and 2026: Non-Current Assets rose 16.18% in 2025, then slipped 9.18% in 2026.
- Over 5 years, Non-Current Assets stood at $7.0 billion in 2022, then advanced by 7.49% to $7.6 billion in 2023, then rose by 15.93% to $8.8 billion in 2024, then decreased by 2.72% to $8.5 billion in 2025, then declined by 5.26% to $8.1 billion in 2026.
- The last three Non-Current Assets figures came in at $8.1 billion (Q2 2026), $8.1 billion (Q1 2026), and $8.5 billion (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 641.14 Bn | 620.38 Bn | 17.26 Bn | 141.29 Bn |
| 2 | AbbVie | 451.04 Bn | 444.47 Bn | 12.70 Bn | 101.45 Bn |
| 3 | Merck | 357.43 Bn | 350.29 Bn | 12.21 Bn | 125.00 Mn |
| 4 | Novartis Ag | 266.73 Bn | 259.04 Bn | 11.24 Bn | 94.68 Bn |
| 5 | Pfizer | 157.52 Bn | 145.82 Bn | 10.94 Bn | 159.77 Bn |
| 6 | Sanofi | 52.14 Bn | 44.76 Bn | 10.79 Bn | 113.37 Bn |
| 7 | Revolution Medicines | 42.88 Bn | 42.88 Bn | - | 294.93 Mn |
| 8 | Incyte | 24.70 Bn | 20.16 Bn | 1.57 Bn | 1.85 Bn |
| 9 | United Therapeutics | 21.47 Bn | 18.80 Bn | 683.80 Mn | 3.74 Bn |
| 10 | Organon | 3.58 Bn | 2.45 Bn | 847.00 Mn | 8.07 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 8.07 Bn |
| Mar 31, 2026 | 8.06 Bn |
| Dec 31, 2025 | 8.52 Bn |
| Sep 30, 2025 | 8.85 Bn |
| Jun 30, 2025 | 8.88 Bn |
| Mar 31, 2025 | 8.79 Bn |
| Dec 31, 2024 | 8.75 Bn |
| Sep 30, 2024 | 8.00 Bn |
| Jun 30, 2024 | 7.65 Bn |
| Mar 31, 2024 | 7.70 Bn |
| Dec 31, 2023 | 7.55 Bn |
| Sep 30, 2023 | 6.96 Bn |
| Jun 30, 2023 | 7.02 Bn |
| Mar 31, 2023 | 6.98 Bn |
| Dec 31, 2022 | 7.02 Bn |
| Sep 30, 2022 | 6.85 Bn |
| Jun 30, 2022 | 6.84 Bn |
| Mar 31, 2022 | 6.88 Bn |
| Dec 31, 2021 | 6.92 Bn |
| Sep 30, 2021 | 7.01 Bn |